Loading…
Cellectar Biosciences, Inc. is projected to rise to $3.08 by 2027, a +16% move from its current price of $2.66. CLRB is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $2.59 | $2.66 | $2.73 | +0.01% |
| Aug 6 | $2.56 | $2.66 | $2.76 | +0.02% |
| Aug 7 | $2.54 | $2.66 | $2.79 | +0.03% |
| Aug 8 | $2.52 | $2.66 | $2.81 | +0.04% |
| Aug 9 | $2.51 | $2.66 | $2.83 | +0.05% |
| Aug 10 | $2.49 | $2.66 | $2.84 | +0.06% |
| Aug 11 | $2.48 | $2.66 | $2.86 | +0.07% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.48 | $2.66 | $2.86 | +0.07% |
| Week 2 | $2.41 | $2.66 | $2.94 | +0.13% |
| Week 3 | $2.36 | $2.67 | $3.01 | +0.20% |
| Week 4 | $2.31 | $2.67 | $3.07 | +0.27% |
| Week 5 | $2.28 | $2.67 | $3.13 | +0.33% |
| Week 6 | $2.25 | $2.67 | $3.18 | +0.40% |
| Week 7 | $2.22 | $2.67 | $3.22 | +0.47% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Cellectar Biosciences, Inc. is a clinical biopharmaceutical company that focuses on discovering, developing, and commercializing drugs for the treatment of cancer in the United States. The company’s lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory Waldenström's macroglobulinemia, relapsed or refractory multiple myeloma, and relapsed or refractory non-Hodgkin's lymphoma; Phase 1 clinical study for relapsed or refractory pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for relapsed or refractory head and neck cancer.
It also develops CLR 121125, an iodine-125 Auger-emitting radioconjugate program; and CLR 225, an actinium-225 based radioconjugate program. The company has collaborations with Orano Med to develop alpha emitter lead-212 conjugated to phospholipid ether series; and LegoChem Bio. Cellectar Biosciences, Inc.
was founded in 2002 and is headquartered in Florham Park, New Jersey.
CLRB is the trading asset with a current price of $2.41 and a micro-cap market position, ranking 4659 with a market cap of $19.26M. The near-term setup reflects a cautious stance given the current technical backdrop, while the longer-run outlook shows potential upside according to the year-by-year price forecast. The stock carries a bearish near-term flavor, even as longer-term forecasts move into bullish territory.
In 2026 the average price is projected at $2.41 with a min of $2.23 and a max of $3.15, and a neutral sentiment. The forecast broadens into a bullish trajectory over the following years, with the average price rising to $3.09 by 2030 and peaking at $9.06 by 2050, supported by a rising max price through the period.
A major floor 17.9% below — a decisive break under it would weaken the trend.
The nearest floor, 9.4% below — buyers have tended to step in here.
The nearest ceiling, 6.4% above — a clean break opens room to run.
A major ceiling 32.7% above — clearing it would confirm fresh momentum.
Key CLRB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CLRB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.50 | Buy | $2.52 | Buy |
| MA 10 | $2.50 | Buy | $2.52 | Buy |
| MA 20 | $2.58 | Buy | $2.55 | Buy |
| MA 50 | $2.65 | Buy | $2.65 | Buy |
| MA 100 | $2.79 | Sell | $2.85 | Sell |
| MA 200 | $3.08 | Sell | $4.46 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 49.66 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | -9.07 | Neutral |
| Williams %R (14) | -27.27 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | -1.53 | Sell |
| Bollinger %B (20,2) | 0.47 | Neutral |
| Stochastic %K (14) | 72.73 | Neutral |
| TRIX (15) | -0.24 | Sell |
| Awesome (5,34) | -0.07 | Sell |
| Ultimate (7,14,28) | 59.46 | Neutral |
| Momentum (10) | 0.06 | Buy |
| Aroon Osc (25) | -64.00 | Sell |
| Hull MA (9) | 2.53 | Buy |
| ADX (14) | 12.02 | Neutral |
| ATR (14) | 0.06 | Info |
The 30-day technical picture is bearish. The RSI14 is 40, and the price is trading below both the SMA50 ($2.72) and the SMA200 ($3.16), indicating downside pressure in the near term. Support sits at $2.23 and resistance at $2.83, suggesting limited upside on a short timeframe.
The 30-day price range spans from $1.98 to $2.93, underscoring the constrained near-term moves.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.23 | $2.66 | $3.42 | 0% | Neutral | |
| $2.46 | $3.08 | $4.07 | +16% | Neutral | |
| $2.62 | $3.38 | $4.63 | +27% | Bullish | |
| $2.77 | $3.65 | $5.15 | +37% | Bullish | |
| $2.60 | $3.50 | $5.06 | +31% | Bullish | |
| $2.59 | $3.54 | $5.23 | +33% | Bullish | |
| $2.65 | $3.69 | $5.55 | +39% | Bullish | |
| $2.61 | $3.69 | $5.66 | +39% | Bullish | |
| $3.10 | $4.44 | $6.91 | +67% | Bullish | |
| $3.42 | $4.97 | $7.85 | +87% | Bullish | |
| $3.78 | $5.87 | $9.85 | +121% | Bullish | |
| $6.04 | $10.50 | $19.25 | +295% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $2.23 | $2.66 | $3.23 | +0.00% |
| September 2026 | $2.33 | $2.75 | $3.34 | +3.40% |
| October 2026 | $2.26 | $2.68 | $3.29 | -2.45% |
| November 2026 | $2.21 | $2.64 | $3.27 | -1.58% |
| December 2026 | $2.28 | $2.74 | $3.42 | +3.69% |
Click any year to see its month-by-month CLRB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Cellectar Biosciences, Inc.'s 2026 outlook centres on $2.66, within a $2.23 to $3.42 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, CLRB could reach as high as $4.07, with a base case around $3.08 and support toward $2.46 — roughly +16% from $2.66. A consolidation phase looks the most probable path here.
Expect CLRB to range from $2.62 to $4.63 through 2028. The $3.38 average target implies a +27% move from current prices. That is up +10% on the projected 2027 average. Momentum favours further upside here.
The CLRB price prediction for 2029 points to an average of $3.65 (low $2.77, high $5.15) — a potential gain of +37% on today's $2.66. Buyers look set to stay in control over this stretch.
In 2030, CLRB is projected to trade between $2.60 and $5.06, averaging $3.50 — a potential gain of +31% from today's $2.66. That is -4% versus the projected 2029 average. Momentum favours further upside here.
Cellectar Biosciences, Inc.'s 2031 outlook centres on $3.54, within a $2.59 to $5.23 range. That is up +1% on the projected 2030 average. That marks a +33% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, CLRB could reach as high as $5.55, with a base case around $3.69 and support toward $2.65 — roughly +39% from $2.66. Momentum favours further upside here.
Expect CLRB to range from $2.61 to $5.66 through 2033. The $3.69 average target implies a +39% move from current prices. That is up 0% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The CLRB price prediction for 2034 points to an average of $4.44 (low $3.10, high $6.91) — a potential gain of +67% on today's $2.66. Momentum favours further upside here.
In 2035, CLRB is projected to trade between $3.42 and $7.85, averaging $4.97 — a potential gain of +87% from today's $2.66. That is up +12% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Cellectar Biosciences, Inc.'s 2040 outlook centres on $5.87, within a $3.78 to $9.85 range. That is up +18% on the projected 2035 average. That marks a +121% change versus current levels. Momentum favours further upside here.
By 2050, CLRB could reach as high as $19.25, with a base case around $10.50 and support toward $6.04 — roughly +295% from $2.66. Buyers look set to stay in control over this stretch.
Investing $1,000 in CLRB today (≈ 375.93985 CLRB) could be worth
$3,945.74
+$2,945.74 (+295%) by 2050 · US Dollar
Based on the average projected CLRB price of $10.5 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CLRBwould be worth at today's price.
$1,000 invested in CLRB on Jul 31, 2025 (≈ 206.611564 CLRB) would be worth
$549.59
-$450.41 (-45.0%) today · 0.55× · US Dollar
Based on a CLRB entry price of $4.84 vs. today's $2.66.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.41 | $1,103.73 | +10.4% |
| 1 month ago | $2.83 | $939.93 | -6.0% |
| 3 months ago | $2.69 | $988.85 | -1.1% |
| 6 months ago | $3.15 | $844.44 | -15.6% |
| 1 year ago | $4.84 | $549.59 | -45.0% |
| All time (5.0y) ago | $306 | $8.69 | -99.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CLRB forecast.
Our base-case forecast reaches $5.30 around 2040.
Implied market cap at $5.30: $42.36M
The multi-year forecast points to a bullish trajectory after a neutral start in 2026, with the average price rising from $2.41 in 2026 to $3.09 in 2030 and to $9.06 by 2050. Notable milestones include a 2030 average of $3.09 with a 28.4% ROI, 2040 average of $5.04 with a 109% ROI, and a 2050 average of $9.06 with a 276.1% ROI. The forecast describes a sustained upward path across 2027–2050, with higher max prices culminating in a substantial long-run upside.
Risks include the inherent uncertainty of long-horizon estimates and the potential for market and treatment-development dynamics to alter price trajectories.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $3.09 with a min of $2.26 and a max of $4.58, and a ROI of 28.4%; sentiment is BULLISH.
Forecasts show a bullish sentiment from 2027 onward, with rising averages and ROIs through 2050 (e.g., average $9.06 and ROI 276.1% in 2050), but these are estimates and not guarantees.
Yes. The 2050 forecast lists a max price of $17.33.
Current price is $2.41 and market cap is $19.26M.
The 30-day range is from $1.98 to $2.93.
Cellectar Biosciences, Inc. Community Discussion
0Share your Cellectar Biosciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.